Skip to main content

Market Outlook: Assessing Readiness for the Next IPO Window

Tuesday, February 27, 2024
Majestic Complex
Biotechnology IPO activity since the 2021 peak is still down more than 70%, tracking with the U.S. Federal Reserve’s lifting of interest rates. As macroeconomic forecasts envision interest rates to start plateauing in the year ahead, IPOs have fewer reasons to delay. This panel will consider the readiness of investors and public markets to increase their support for biomedical innovation as well as explain how the bold companies that have launched this year built their appeal to stand out.
Susan Roberts, Founder - Roberts Communications
James Antonopoulos, Managing Director, Head of Healthcare Banking - ROTH MKM
Johanna Grossman, Head of Healthcare & Life Sciences, Capital Markets - New York Stock Exchange
Ryan Starkes, Partner, Life Sciences Practice Leader & Raleigh Market Leader - Centri Consulting
Adam Stone, Chief Investment Officer & Head of Research - Perceptive Advisors

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.